For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Adc Therapeutics SA’s stock clocked out at $4.54, up 5.34% from its previous closing price of $4.31. In other words, the price has increased by $5.34 from its previous closing price. On the day, 1.2 million shares were traded. ADCT stock price reached its highest trading level at $4.62 during the session, while it also had its lowest trading level at $4.3.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share. On Dec 04 ’24, another insider, Redmile Group, LLC, who serves as the 10% Owner of the company, sold 25,352 shares for $2.07 each. As a result, the insider received 52,479 and left with 15,566,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 510747232 and an Enterprise Value of 696954240. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.61. Its current Enterprise Value per Revenue stands at 9.023 whereas that against EBITDA is -5.525.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.97, which has changed by 0.65693426 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $4.67, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 36.82%, while the 200-Day Moving Average is calculated to be 90.92%.
Shares Statistics:
It appears that ADCT traded 805.00K shares on average per day over the past three months and 1347720 shares per day over the past ten days. A total of 112.50M shares are outstanding, with a floating share count of 88.15M. Insiders hold about 21.64% of the company’s shares, while institutions hold 58.98% stake in the company. Shares short for ADCT as of 1757894400 were 4069052 with a Short Ratio of 5.05, compared to 1755216000 on 4514712. Therefore, it implies a Short% of Shares Outstanding of 4069052 and a Short% of Float of 4.46.
Earnings Estimates
The firm’s stock currently is rated by 7.0 analysts. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.23 and low estimates of -$0.43. Analysts are recommending an EPS of between -$1.38 and -$1.73 for the fiscal current year, implying an average EPS of -$1.53. EPS for the following year is -$1.3, with 5.0 analysts recommending between -$0.8 and -$1.97.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $18.85M. It ranges from a high estimate of $19.3M to a low estimate of $17.8M. As of. The current estimate, Adc Therapeutics SA’s year-ago sales were $18.46MFor the next quarter, 5 analysts are estimating revenue of $18.75M. There is a high estimate of $19.6M for the next quarter, whereas the lowest estimate is $17.5M.
A total of 5 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $80.7M, while the lowest revenue estimate was $77.1M, resulting in an average revenue estimate of $79.47M. In the same quarter a year ago, actual revenue was $70.84MBased on 4 analysts’ estimates, the company’s revenue will be $84.2M in the next fiscal year. The high estimate is $102.3M and the low estimate is $72.6M.
